Epidermolysis bullosa is a group of rare genetic disorders that cause easy blistering of the skin and mucous membranes. The condition ranges from mild to severe forms with pain and risk of infection. Current treatments focus on dressing and bandaging of wounds, antibiotics to prevent infection and specialized wound care. The global EB market has seen a rise in introduction of new treatment options like gene therapy and bioengineered skin substitutes which help address wound healing in a more effective manner. The global Epidermolysis Bullosa (EB) Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of epidermolysis bullosa disorders globally is a key trend fueling market growth. It is estimated that half a million people worldwide are affected by some form of EB, with birth incidence ranging between 1 in 17,000 to 1 in 200,000 newborns. Since there is no cure, advanced treatment approaches like gene therapy and cell therapies offer hope to patients. Several clinical trials are ongoing to evaluate the safety and efficacy of these novel treatment modalities. Their successful development will help address the significant unmet needs of EB patients.
Strength: The rising prevalence of epidermolysis bullosa and increasing investment in research and development present growth opportunities. The increasing healthcare awareness also supports the market growth.
Weakness: The disease has no cure currently and the only treatment options provide symptomatic relief. This limits the growth potential of the market. Lack of skilled professionals also impacts the market negatively.
Opportunity: The increasing adoption of orphan drugs presents an opportunity for key players. The emergence of bioengineered skins and gene therapies also opens new avenues. Collaborations between industry and academia further boost research activities.
Threats: High treatment costs associated with therapies pose affordability challenges. Stringent regulations for drug approval can delay market entry. Delays in clinical trial processes also impact market growth adversely.
The global epidermolysis bullosa market is expected to witness high growth in the forecast period from 2023 to 2030.
Regional Analysis: North America is currently dominating the market owing to strong healthcare infrastructure and research funding. The region accounted for over 35% share in 2024 and is projected to maintain its dominance till 2030. Europe holds the second largest market share due to increasing awareness initiatives by key players.
Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi. Amryt Pharma leads the market and has a strong pipeline of orphan and rare disease products. RegeneRx is a clinical-stage regenerative medicine company focused on developing novel therapies for severe wounds and skin defects. Castle Creek Pharmaceuticals is progressing clinical trials for potential gene therapies.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it